BioSpace News Archive

Drug Development

Revolution Medicines to Present Preliminary Data from Phase 1 Clinical Trial of RMC-4630 at 6th AACR-IASLC International Joint Conference

Podium and Poster Presentations to Highlight Initial Findings from Monotherapy Study of Investigational SHP2 Inhibitor, RMC-4630 Additional Poster Presentation to Report New Preclinical Results for Company’s Novel Inhibitors of Oncogenic RAS(ON) mutants

January 7, 2020
·
4 min read
Nuvo Pharmaceuticals Announces Repayment of Bridge Loan and Entitlement to Receive 2019 Vimovo U.S. Annual Minimum Royalty

The Company has received US$5.6 million to-date.

January 7, 2020
·
7 min read
Business

Bridge Bank’s Life Sciences Group Expands in San Francisco Bay Area, Hires Derek Scalf

Announces Return to 38th Annual JP Morgan Healthcare Conference

January 7, 2020
·
2 min read
ZYUS and University of Saskatchewan Partner to Conduct Cannabinoid-Based Research on Possible Treatment of Brain Disorders

Pre-clinical study seeks to determine the impact of cannabis derivatives on mental health conditions

January 7, 2020
·
5 min read
Drug Development

Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Based on continued encouraging efficacy and safety data, metastatic castration-resistant prostate cancer cohort further expanded to 130 patients

January 7, 2020
·
13 min read
Job Trends

Clovis Oncology Announces Debt Refinancing Transaction

J.P. Morgan and BofA Securities acted as the exclusive agents to the Company in connection with the Transactions.

January 7, 2020
·
3 min read
Study Shows HK L-137 Reduces Inflammation in Healthy Overweight Individuals — Takes Front Line Against Metabolic Syndrome

It’s why House Wellness Foods has put decades of meticulous research into the anti-inflammatory benefits of its unique immunobiotic Lactobacillus plantarum HK L-137, the primary ingredient of its Immuno-LP20®.

January 7, 2020
·
4 min read
Business

Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing

Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors, today announced the appointment of Christopher Ballas, Ph.D., as Senior Vice President of Manufacturing.

January 7, 2020
·
3 min read
Genetown

Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference

Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will present at the 38th Annual J.P.Morgan Healthcare Conference

January 7, 2020
·
1 min read
Drug Development

Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate CancerADXS-504 is the Company’s second drug product candidate from the HOT program to receive IND clearance from FDA

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the initiation of a Phase 1 clinical study of ADXS-504, the Company’s ADXS-HOT candidate for prostate cancer.

January 7, 2020
·
3 min read